Biological Effects of Hydrogen Water on Subjects with NAFLD: A Randomized, Placebo-Controlled Trial
Kura B et al. · Antioxidants (Basel). 2022;11(10):1935.
Study at a glance
Human
Adults with non-alcoholic fatty liver disease
One tablet dissolved in 330 mL water, three times daily; approximately 990 mL/day · >4 mg/L dissolved H₂; more than 12 mg H₂/day reported.
8 weeks
Most changes were non-significant trends. Liver enzymes did not significantly change; MDA and 8-OHdG showed mild non-significant increases. The authors state that clinical implications are unclear.
Small trial with many biomarkers and mostly non-significant findings. HRW Natural Health Products funded part of the work and Alex Tarnava supplied hydrogen and placebo tablets, although the authors declared no conflict.
What kind of evidence is this?
Human
Randomized double-blind placebo-controlled trial
Liver health
H₂-rich water
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
Adults with non-alcoholic fatty liver disease
30 participants: H₂ water n=17, placebo n=13
8 weeks
One tablet dissolved in 330 mL water, three times daily; approximately 990 mL/day
H₂ dissolved in water — H₂ only, not Brown’s gas.
>4 mg/L dissolved H₂; more than 12 mg H₂/day reported.
Matched tablets producing CO₂ rather than H₂, taken in the same water volume
Outcomes and reported result
Weight, BMI, liver enzymes, lipid profile, inflammatory and oxidative-stress biomarkers
Most changes were non-significant trends. Liver enzymes did not significantly change; MDA and 8-OHdG showed mild non-significant increases. The authors state that clinical implications are unclear.
Methods, results, funding and commercial support checked in the free full text; independent appraisal remains incomplete.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Small trial with many biomarkers and mostly non-significant findings. HRW Natural Health Products funded part of the work and Alex Tarnava supplied hydrogen and placebo tablets, although the authors declared no conflict.
Adults with NAFLD meeting this trial’s criteria.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 36290657 · DOI: 10.3390/antiox11101935
Open-access article.
Free full text on PMC and publisher page; identifiers cross-checked in PubMed.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.